Logo

Horizon Reports Results of HZN-4920 in P-II Study for Rheumatoid Arthritis

Share this

Horizon Reports Results of HZN-4920 in P-II Study for Rheumatoid Arthritis

Shots:

  • The P-II study evaluates dazodalibep (HZN-4920) vs PBO in 75 subjects with active, moderate-to-severe, adult-onset RA. Patients were randomized into four different dosing regimens
  • The study met its 1EPs change from baseline in DAS28-CRP @Day 113 in all four dazodalibep dosing arms. The therapy was well tolerated
  • In the P-II trial, the last dose of dazodalibep was given @Day 85 and follow-up data @Day 169 showed a prolonged and sustained benefit on disease activity. The study follows the P-Ib, multiple ascending dose study in patients with active moderate-to-severe RA

Ref: Horizon Therapeutics | Image: Horizon

Click here to­ read the full press release 

Senior Editor

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions